Discontinuation of antidementia medication in extremely severe dementia patients: a 12-week randomized multicenter trial

Discontinuation of Donepezil or Memantine in Extremely Severe Alzheimer`s Disease Patients : A 12-Week, Randomized, Multi-center Trial

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

CRIS

Registry ID

KCT0000874

Enrollment

120

Registered

2013-10-08

Start date

2013-02-12

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : Stop donepezil (5/10mg) or memantine (10/20mg) treatment for 3 months in Alzheimer's disease and compare the outcome variables between discontinuation group and continuation group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients fulfilling DSM-IV criteria for dementia 2. Patients fulfilling NINCDS-ADRDA possible or probable AD (Alzheimer’s disease) 3. aged between 65 to 100 years old 4. caregiver who can give full information about patient should exist 5. same antidementia and antipsychotic medications at least 2 months before study enrollment 6. patients who can visit hospital at every follow up 7. K-MMSE =5 and FAST score 6a or less

Exclusion criteria

Exclusion criteria: 1. severe uncontrolled medical condition 2. other degenerative brain diesase or psychiatric disease which can cause dementia 3. 2 or more antidementia medication(excluding brain pill). 4. patients or caregivers do not accept the study

Design outcomes

Primary

Measure	Time frame
BPMSE score;CGI-C score	—

Secondary

Measure	Time frame
ESDQ score;NPI score;CMAI score;CDR score;CDR-SOB score;FAST score;ADCS-ADL-severe score;K-MMSE score;B-ADL score;HIS (Hachinski ischemic scale) score;study-related medical complication ;study-related mortality	—

Countries

Korea, Republic of

Contacts

Public ContactYunJeong Hong

Hyoja Geriatric Hospital

Outcome results